道彤投资
@author-1784793658606
以生命科学为根，向硬科技生长
Articles
Vol. 2 The "Efficiency Code" of Bio-Manufacturing: AI Gives Enzymes a 7-Day Iteration Engine | Column · The New Era's Unicorns
The bio-manufacturing industry will undergo structural transformation around 2030.
Vol.1 Finding a Switch for That Chronic Pain You've Endured for So Long | Column · The New Era's Unicorns
In 2025, the global chronic pain treatment market will grow to 500 billion yuan.
Xinyun Medical Closes Tens of Millions of RMB in Series B+ Funding Led by Dalton Venture, Building Innovative Devices and Neuromodulation Solutions for Chronic Pain | Dalton News
AI is emerging as a new engine for breaking through in pain treatment
Triastek Secures China's First 3D-Printed Drug Manufacturing License, Marking a New Era of Digital Innovation in Chinese Pharma | DaoTong Family
In September 2025, **Triastek, a Dalton Venture portfolio company, received the nation's first Pharmaceutical Manufacturing License for 3D-printed drug production issued by the Jiangsu Provincial Medical Products Administration**. This marks the first time that 3D printing pharmaceutical technology in China has achieved compliant, regulated manufacturing. It represents a critical step forward for Triastek in drug R&D and industrialization, as well as another milestone for Dalton Venture's investments in pharmaceutical innovation.
Jinggou Biotech Closes Tens of Millions of Yuan in Series A Funding, Dalton Venture Bets on Synthetic Biology for Nutrition and Health | Dalton News
Recently, emerging Chinese synthetic biology company **Hangzhou Jinggou Biotechnology Co., Ltd. (hereinafter referred to as "Jinggou Bio") announced the completion of a Series A financing round worth tens of millions of RMB, with Dalton Venture participating in the investment.** Proceeds from this round will be primarily directed toward R&D investment and production base capacity building, accelerating the scaled production of high-value-added nutritional health and feed additive products, and advancing the commercialization of green bio-manufacturing.
China's First Batch! Astribot Secures Thousand-Unit AI Robot Order, Ushering in a New Chapter of Large-Scale Industrial Agent Deployment | Tong's Family
Recently, **Astribot, a member of the Datong Family**, announced a strategic partnership with SEER Intelligence for a thousand-unit humanoid robot order. Over the next two years, the two companies will drive the large-scale, phased deployment of over a thousand AI robots across industrial, manufacturing, warehousing, and logistics scenarios. This collaboration marks a new phase of "industrial intelligent agent" applications for AI robots, sets a benchmark for the commercialization of embodied intelligence technology, and represents a significant step in advancing "new quality productive forces."
"The Made-in-China" Breakthrough Moment: DaYi Group and Hanno Medical Featured in Xinhua News Agency Report | TongNews
On August 27, Xinhua News Agency published a special report titled *"More and More 'Made in China': China's Medical Equipment Achieves New Breakthroughs"*, comprehensively presenting the leapfrog development of China's medical equipment industry since the 14th Five-Year Plan period. In the report, **TAICHI Medical Systems** and **Hanano Medical**, two portfolio companies of **Dowstone Capital**, were specifically named, with their product innovation achievements drawing attention. This reflects not only the breakthrough capabilities of the enterprises themselves, but also the acceleration of China's medical equipment industry toward self-reliance and comprehensive —
Dalton Venture's Sun Qi: Focus, Steady Rhythm, Multiple Paths — Actively Positioning Through the Cycle | Dalton Insights
On July 3–4, 2025, **the 19th China Fund Partners Conference, co-hosted by Zero2IPO and PEDaily, was held in Shanghai**. This year's gathering brought together capital leaders to discuss industry trends, examine the latest dynamics in China's LP market, and explore the path forward for venture capital in a new cycle. **Dalton Venture founding and managing partner Sam Sun was invited to join the roundtable forum *"Cycle Positioning, Investment Strategies"*** to exchange views with fellow guests on the evolution of investment cycles and responsive strategies.
Aiyisheng Completes Angel Round with DaoTong as Sole Investor, Accelerating Clinical Trials for Small-Caliber Artificial Blood Vessels | DaoTong News
Recently, **Aison (Guangzhou) Biotech Co., Ltd.** (hereinafter referred to as Aison Medical) **announced the completion of its angel round, led exclusively by Dalton Venture.** The proceeds will be primarily used to advance the clinical development of small-diameter artificial blood vessels and to expand applications of its core technology.
How Does Dalton Venture Precisely Capture Investment Growth Opportunities by Focusing on Cardiovascular Disease Diagnosis, Treatment, and Management? | Dalton Insights
For decades, cardiovascular disease has been considered the "leading killer" threatening global human health and longevity, with mortality rates reaching 5% among patients over 65. As population aging accelerates and lifestyles shift, the prevalence of chronic heart conditions is rising markedly — spurring waves of innovation across cardiovascular device segments to address persistent treatment pain points and improve diagnostic and therapeutic efficiency and safety.